Cargando…

Efficacy and Improved Resistance Potential of a Cofactor-Independent InhA Inhibitor of Mycobacterium tuberculosis in the C3HeB/FeJ Mouse Model

AN12855 is a direct, cofactor-independent inhibitor of InhA in Mycobacterium tuberculosis. In the C3HeB/FeJ mouse model with caseous necrotic lung lesions, AN12855 proved efficacious with a significantly lower resistance frequency than isoniazid. AN12855 drug levels were better retained in necrotic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Robertson, Gregory T., Ektnitphong, Victoria A., Scherman, Michael S., McNeil, Matthew B., Dennison, Devon, Korkegian, Aaron, Smith, Anthony J., Halladay, Jason, Carter, David S., Xia, Yi, Zhou, Yasheen, Choi, Wai, Berry, Pamela W., Mao, Weimin, Hernandez, Vincent, Alley, M. R. K., Parish, Tanya, Lenaerts, Anne J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2019
Materias:	Experimental Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6496157/ https://www.ncbi.nlm.nih.gov/pubmed/30745397 http://dx.doi.org/10.1128/AAC.02071-18

Ejemplares similares

Discovery of a cofactor-independent inhibitor of Mycobacterium tuberculosis InhA
por: Xia, Yi, et al.
Publicado: (2018)

Drug distribution and efficacy of the DprE1 inhibitor BTZ-043 in the C3HeB/FeJ mouse tuberculosis model
por: Ramey, Michelle E., et al.
Publicado: (2023)

InhA inhibitors have activity against non-replicating Mycobacterium tuberculosis
por: Flint, Lindsay, et al.
Publicado: (2020)

Comparative Analysis of Pharmacodynamics in the C3HeB/FeJ Mouse Tuberculosis Model for DprE1 Inhibitors TBA-7371, PBTZ169, and OPC-167832
por: Robertson, Gregory T., et al.
Publicado: (2021)

Heterogeneous disease progression and treatment response in a C3HeB/FeJ mouse model of tuberculosis
por: Lanoix, Jean-Philippe, et al.
Publicado: (2015)

In-Vivo Gene Signatures of Mycobacterium tuberculosis in C3HeB/FeJ Mice
por: Gautam, Uma Shankar, et al.
Publicado: (2015)

Mycobacterium avium Infection in a C3HeB/FeJ Mouse Model
por: Verma, Deepshikha, et al.
Publicado: (2019)

Catheter-associated Mycobacterium intracellulare biofilm infection in C3HeB/FeJ mice
por: Yamamoto, Kentaro, et al.
Publicado: (2023)

Presence of multiple lesion types with vastly different microenvironments in C3HeB/FeJ mice following aerosol infection with Mycobacterium tuberculosis
por: Irwin, Scott M., et al.
Publicado: (2015)

Bedaquiline and Pyrazinamide Treatment Responses Are Affected by Pulmonary Lesion Heterogeneity in Mycobacterium tuberculosis Infected C3HeB/FeJ Mice
por: Irwin, Scott M., et al.
Publicado: (2016)

Temporal analysis of mRNA expression profiles in Orientia infected C3HeB/FeJ mouse
por: Chao, Chien-Chung, et al.
Publicado: (2020)

Oral Administration of Heat-Killed Mycobacterium manresensis Delays Progression toward Active Tuberculosis in C3HeB/FeJ Mice
por: Cardona, Paula, et al.
Publicado: (2016)

Influence of Gut Microbiota on Progression to Tuberculosis Generated by High Fat Diet-Induced Obesity in C3HeB/FeJ Mice
por: Arias, Lilibeth, et al.
Publicado: (2019)

Binding Thermodynamics and Dissociation Kinetics Analysis Uncover the Key Structural Motifs of Phenoxyphenol Derivatives as the Direct InhA Inhibitors and the Hotspot Residues of InhA
por: Zhang, Qianqian, et al.
Publicado: (2022)

The C3HeB/FeJ mouse model recapitulates the hallmark of bovine tuberculosis lung lesions following Mycobacterium bovis aerogenous infection
por: Bouté, Mélodie, et al.
Publicado: (2017)

Fragment-Based Design of Mycobacterium tuberculosis InhA Inhibitors
por: Sabbah, Mohamad, et al.
Publicado: (2020)

Correction to Fragment-Based Design of Mycobacterium tuberculosis InhA Inhibitors
por: Sabbah, Mohamad, et al.
Publicado: (2020)

Longer-Term Omega-3 LCPUFA More Effective Adjunct Therapy for Tuberculosis Than Ibuprofen in a C3HeB/FeJ Tuberculosis Mouse Model
por: Hayford, Frank E. A., et al.
Publicado: (2021)

Pattern of InhA and KatG mutations in isoniazid monoresistant Mycobacterium tuberculosis isolates
por: Charan, Ashok Singh, et al.
Publicado: (2020)

Clarity with INHindsight: High-Dose Isoniazid for Drug-Resistant Tuberculosis with inhA Mutations
por: Wasserman, Sean, et al.
Publicado: (2020)

In silico study of phytochemicals contained in Brucea javanica in inhibiting the InhA enzyme as antituberculosis
por: Sulistyowaty, Melanny Ika, et al.
Publicado: (2023)

Spatial multiomic profiling reveals the novel polarization of foamy macrophages within necrotic granulomatous lesions developed in lungs of C3HeB/FeJ mice infected with Mycobacterium tuberculosis
por: Seto, Shintaro, et al.
Publicado: (2022)

Effect of the explicit flexibility of the InhA enzyme from Mycobacterium tuberculosis in molecular docking simulations
por: Cohen, Elisangela ML, et al.
Publicado: (2011)

Molecular Dynamics Assisted Mechanistic Study of Isoniazid-Resistance against Mycobacterium tuberculosis InhA
por: Kumar, Vivek, et al.
Publicado: (2015)

Antitubercular drugs for an old target: GSK693 as a promising InhA direct inhibitor
por: Martínez-Hoyos, María, et al.
Publicado: (2016)

Screening of a Novel Fragment Library with Functional Complexity against Mycobacterium tuberculosis InhA
por: Prati, Federica, et al.
Publicado: (2018)

The Value of the inhA Mutation Detection in Predicting Ethionamide Resistance Using Melting Curve Technology
por: Song, Yanhua, et al.
Publicado: (2021)

Correlation of inhA mutations and ethionamide susceptibility: Experience from national reference center for tuberculosis
por: Sarin, Rohit, et al.
Publicado: (2021)

Inducing vulnerability to InhA inhibition restores isoniazid susceptibility in drug resistant Mycobacterium tuberculosis
por: Harrison, Gregory A., et al.
Publicado: (2023)

Bacillus anthracis Protease InhA Increases Blood-Brain Barrier Permeability and Contributes to Cerebral Hemorrhages
por: Mukherjee, Dhritiman V., et al.
Publicado: (2011)

Minor Contribution of inhA-15 Mutations to the Rapid Detection of Isoniazid Resistance in Mycobacterium Tuberculosis Isolates
por: Abkar, Roya, et al.
Publicado: (2016)

An Effective Approach for Clustering InhA Molecular Dynamics Trajectory Using Substrate-Binding Cavity Features
por: De Paris, Renata, et al.
Publicado: (2015)

Detection of KatG/inhA Mutation to Guide Isoniazid and Ethionamide Use for Drug-resistant Tuberculosis
por: Namburete, Evangelina
Publicado: (2017)

Anti-tubercular activity and molecular docking studies of indolizine derivatives targeting mycobacterial InhA enzyme
por: Venugopala, Katharigatta N., et al.
Publicado: (2021)

A Structural and Energetic Model for the Slow-Onset Inhibition of the Mycobacterium tuberculosis Enoyl-ACP Reductase InhA
por: Li, Huei-Jiun, et al.
Publicado: (2014)

Slow-Onset Inhibition of Mycobacterium tuberculosis InhA: Revealing Molecular Determinants of Residence Time by MD Simulations
por: Merget, Benjamin, et al.
Publicado: (2015)

A selective method for optimizing ensemble docking-based experiments on an InhA Fully-Flexible receptor model
por: De Paris, Renata, et al.
Publicado: (2018)

InhA1-Mediated Cleavage of the Metalloprotease NprA Allows Bacillus cereus to Escape From Macrophages
por: Haydar, Abbass, et al.
Publicado: (2018)

InhA, the enoyl-thioester reductase from Mycobacterium tuberculosis forms a covalent adduct during catalysis
por: Vögeli, Bastian, et al.
Publicado: (2018)

In Silico Repositioning of Cannabigerol as a Novel Inhibitor of the Enoyl Acyl Carrier Protein (ACP) Reductase (InhA)
por: Pinzi, Luca, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_9c88qj5q7vsjhupva4a2ksdrq7